Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma
NCT06407973 · Sight Sciences, Inc. · PHASE4 · terminated · last registry update 2025-01-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business decision by the Sponsor” | – | Registry record, Sight Sciences, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-26Also stopped (terminated): Baylor Research Institute, Pitocin (NCT02910115)
- 2026-01-21Phase 3 first posted: Qlaris Bio, Inc., QLS-111-FDC + Latanoprost (0.005%) (NCT07354516)
- 2025-10-20Phase 3 first posted: SpyGlass Pharma, Inc., Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5% (NCT07218783)
- 2025-10-20Phase 3 first posted: SpyGlass Pharma, Inc., Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5% (NCT07218796)
- 2025-10-16Results posted on the registry: Brigham and Women's Hospital, 15-methyl prostaglandin F2α + Methylergonovine Maleate (NCT03584854)
- 2025-10-15Also stopped (terminated): Massachusetts Eye and Ear Infirmary, Latanoprost eluting contact lens + Topical Latanoprost (NCT04500574)
- 2025-08-26Results posted on the registry: University of Miami, Latanoprost + Bimatoprost (NCT02390284)
- 2025-08-26Also stopped (terminated): University of Miami, Latanoprost + Bimatoprost (NCT02390284)
- 2025-07-24Phase 3 first posted: Alcon Research, Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution + Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NCT07082816)
- 2025-05-30Results posted on the registry: Nicox Ophthalmics, Inc., NCX 470 0.065% (initial phase of trial) + Latanoprost 0.005% (initial phase of trial) (NCT04445519)
- 2025-05-07Phase 3 first posted: University Hospital Dubrava, Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution + Placebo (NCT06960629)
- 2024-10-31Phase 3 first posted: Santen Pharmaceutical Co., Ltd., DE-117B Eye Drops + Latanoprost (NCT06666855)
- 2024-10-15Results posted on the registry: Glaukos Corporation, Travoprost Intracameral Implant exchanged at Month 12 + Travoprost Intracameral Implant exchanged at Month 3 (NCT06582732)
- 2024-10-01Results posted on the registry: Ocular Therapeutix, Inc., OTX-TIC (NCT04360174)
- 2024-08-23Also stopped (terminated): CT Glaucoma Associates, dorzolamide/timolol (NCT06369077)
- 2024-08-21Also stopped (withdrawn): Nova Scotia Health Authority, Prostagladin (NCT01704989)
- 2024-07-05Also stopped (terminated): Laboratorios Sophia S.A de C.V., PRO-067 + GAAP Ofteno® (NCT02801617)
- 2024-05-28Results posted on the registry: Santen SAS, DE-130A + Xalatan® (NCT04133311)
- 2024-05-10Also stopped (suspended): JeniVision, Inc., JV-GL1 + Latanoprost 0.005% Ophthalmic Solution (NCT04761705)
- 2024-05-10Results posted on the registry: AbbVie, Bimatoprost SR + Sham Bimatoprost SR (NCT02507687)
- 2024-04-03Results posted on the registry: Aerie Pharmaceuticals, Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution (NCT05283395)
- 2024-03-15Results posted on the registry: Santen Pharmaceutical Co., Ltd., DE-117 + Latanoprost ophthalmic solution (NCT02981446)
- 2024-03-04Also stopped (withdrawn): Bausch & Lomb Incorporated, Latanoprostene Bunod + Placebo (NCT04140279)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision